HK1215703A1 - -二氨基- -氯- -苯基丁基 甲脒基 吡嗪- -甲酰胺化合物 - Google Patents

-二氨基- -氯- -苯基丁基 甲脒基 吡嗪- -甲酰胺化合物

Info

Publication number
HK1215703A1
HK1215703A1 HK16103648.2A HK16103648A HK1215703A1 HK 1215703 A1 HK1215703 A1 HK 1215703A1 HK 16103648 A HK16103648 A HK 16103648A HK 1215703 A1 HK1215703 A1 HK 1215703A1
Authority
HK
Hong Kong
Prior art keywords
carbamimidoyl
phenylbutyl
pyrazine
diamino
chloro
Prior art date
Application number
HK16103648.2A
Other languages
English (en)
Inventor
Michael R Johnson
Original Assignee
Parion Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2013/075093 external-priority patent/WO2014099673A1/en
Application filed by Parion Sciences Inc filed Critical Parion Sciences Inc
Publication of HK1215703A1 publication Critical patent/HK1215703A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C07D241/34—(Amino-pyrazine carbonamido) guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
HK16103648.2A 2012-12-17 2016-03-30 -二氨基- -氯- -苯基丁基 甲脒基 吡嗪- -甲酰胺化合物 HK1215703A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261738262P 2012-12-17 2012-12-17
PCT/US2013/075093 WO2014099673A1 (en) 2012-12-17 2013-12-13 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds

Publications (1)

Publication Number Publication Date
HK1215703A1 true HK1215703A1 (zh) 2016-09-09

Family

ID=49911820

Family Applications (3)

Application Number Title Priority Date Filing Date
HK16103648.2A HK1215703A1 (zh) 2012-12-17 2016-03-30 -二氨基- -氯- -苯基丁基 甲脒基 吡嗪- -甲酰胺化合物
HK16103650.7A HK1215704A1 (zh) 2012-12-17 2016-03-30 經芳烷基和氧基取代的上皮鈉通道阻斷化合物
HK18114809.2A HK1255811A1 (zh) 2012-12-17 2018-11-20 經芳烷基和氧基取代的上皮鈉通道阻斷化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK16103650.7A HK1215704A1 (zh) 2012-12-17 2016-03-30 經芳烷基和氧基取代的上皮鈉通道阻斷化合物
HK18114809.2A HK1255811A1 (zh) 2012-12-17 2018-11-20 經芳烷基和氧基取代的上皮鈉通道阻斷化合物

Country Status (15)

Country Link
EP (2) EP2931711B1 (zh)
JP (2) JP6392243B2 (zh)
KR (1) KR102258465B1 (zh)
CN (2) CN104955812B (zh)
AU (2) AU2013363247B2 (zh)
BR (1) BR112015014062A2 (zh)
CA (2) CA2896686A1 (zh)
ES (3) ES2674665T3 (zh)
HK (3) HK1215703A1 (zh)
IL (2) IL239410A (zh)
MX (1) MX2015007798A (zh)
NZ (1) NZ709199A (zh)
RU (1) RU2015129076A (zh)
WO (1) WO2014099705A1 (zh)
ZA (1) ZA201504560B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36034A (es) 2014-03-18 2015-09-30 Astrazeneca Ab Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos
US10577308B2 (en) 2015-03-26 2020-03-03 The Florey Institute Sodium channel modulators
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318813A (en) 1965-08-16 1967-05-09 Dow Chemical Co Poly-alkylstyrene viscosity index improver
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
US4312860A (en) 1980-10-24 1982-01-26 Regents Of The University Of California Lung surfactant compositions
US4479932A (en) 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
US5100806A (en) 1989-03-24 1992-03-31 Macri James N Method for detecting Edwards syndrome
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
CA2063273C (en) 1989-07-11 2002-09-24 Bradley J. Benson Surfactant compositions and methods
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5614216A (en) 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
US5292498A (en) 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
JP3230056B2 (ja) 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
ATE150296T1 (de) 1991-12-18 1997-04-15 Minnesota Mining & Mfg Aerosolzusammensetzungen für arzneimittelsuspensionen
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5656256A (en) 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
PL180895B1 (pl) 1995-04-14 2001-04-30 Glaxo Wellcome Inc Inhalator z dozymetrem
NZ337225A (en) 1997-02-06 2002-03-28 Inspire Pharmaceuticals Inc Dinucleotides useful for treating chronic pulmonary obstructive disorder
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US7223744B2 (en) 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
ATE347880T1 (de) 1998-10-20 2007-01-15 Univ North Carolina Methoden zum befeuchten der nasenschleimhaut
US6329034B1 (en) 1999-01-18 2001-12-11 Roger L. Pendry Label having tab member and methods for forming, applying and using the same
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
IL146886A0 (en) 1999-06-05 2002-08-14 Innovata Biomed Ltd Medicament delivery system
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
DE60012347T2 (de) 1999-10-12 2005-07-28 Shl Medical Ab Inhalator
PT1666028E (pt) 1999-10-29 2010-06-15 Novartis Ag Composições de pós anidros com melhor dispersividade
GB9928265D0 (en) 1999-12-01 2000-01-26 Innovata Biomed Ltd Inhaler
SE9904706D0 (sv) 1999-12-21 1999-12-21 Astra Ab An inhalation device
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
US7171965B2 (en) 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
FR2813593B1 (fr) 2000-09-07 2002-12-06 Valois Sa Dispositif de distribution de produit fluide de type multidose
GB0026647D0 (en) 2000-10-31 2000-12-13 Glaxo Group Ltd Medicament dispenser
GB2377532B (en) 2001-07-11 2005-06-29 Sendo Int Ltd Communications devices operable to electronically process text data for representing characters of a text message, and methods for operating such devices
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6889690B2 (en) 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
CA2493458A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
ES2926542T3 (es) 2003-04-11 2022-10-26 Ptc Therapeutics Inc Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para supresión de mutaciones finalizadoras y el tratamiento de enfermedades
EP1488819A1 (en) 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
KR20060115348A (ko) 2003-08-18 2006-11-08 패리온 사이언스 인코퍼레이티드 지방족 피라지노일구아니딘 나트륨 채널 차단제
AU2004264441A1 (en) 2003-08-18 2005-02-24 Parion Sciences, Inc. Cyclic pyrazinoylguanidine sodium channel blockers
WO2005018644A1 (en) 2003-08-18 2005-03-03 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) * 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
DE10339710A1 (de) 2003-08-22 2005-03-17 Siemens Ag Verfahren zur Zulassungsanfrage zu einem Datenzugriff auf Nutzungs- und Zustandsdaten von Mobilfunkteilnehmern in einem Mobilfunknetz
US7499570B2 (en) 2004-03-02 2009-03-03 Siemens Corporate Research, Inc. Illumination invariant change detection
US6887597B1 (en) 2004-05-03 2005-05-03 Prestone Products Corporation Methods and composition for cleaning and passivating fuel cell systems
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
KR20070052317A (ko) 2004-08-18 2007-05-21 마이클 알 존슨. 환형 아미드 및 에스테르 피라지노일구아니딘 나트륨 채널차단제
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
JP2008510702A (ja) 2004-08-18 2008-04-10 マイケル・アール・ジョンソン 脂肪族アミド及びエステルピラジノイルグアニジンナトリウムチャネル遮断薬
EP1799212A2 (en) 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
US7507809B2 (en) 2005-01-07 2009-03-24 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV and therapeutic uses thereof
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
US20090306009A1 (en) 2005-12-06 2009-12-10 P2-Science Aps Modulation of the P2Y2 Receptor Pathway
WO2007075946A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
JP5457680B2 (ja) 2006-01-24 2014-04-02 アンサン バイオファーマ，インコーポレイテッド 高分子マイクロスフェアの調製技術
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
CA2652072A1 (en) 2006-05-12 2007-11-22 Vertex Pharmaceuticals Incorporated Compositions of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2654244A1 (en) 2006-06-09 2007-12-21 Parion Sciences, Inc. Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity
CN101534813A (zh) * 2006-09-07 2009-09-16 帕里昂科学公司 通过使用钠通道阻断剂和渗透调节剂的治疗来增加粘膜水化和粘液清除的方法
US8058278B2 (en) 2006-09-07 2011-11-15 Parion Sciences, Inc. Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
JP2010502739A (ja) * 2006-09-07 2010-01-28 パリオン・サイエンシィズ・インコーポレーテッド ナトリウムチャネル阻害剤及び浸透圧調節物質を用いた処置による粘膜水和及び粘液クリアランスの改善
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2152316A4 (en) 2007-04-26 2011-03-23 Quark Pharmaceuticals Inc THERAPEUTIC DELIVERY OF INHIBITORY NUCLEIC ACID MOLECULES IN THE RESPIRATORY SYSTEM
EP1997502A1 (en) 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
EP2173327A2 (en) 2007-07-24 2010-04-14 Nexbio, Inc. Technology for the preparation of microparticles
WO2009061368A1 (en) 2007-11-06 2009-05-14 Benaroya Research Institute Inhibition of versican with sirna and other molecules
TWI439462B (zh) * 2007-12-10 2014-06-01 Novartis Ag 作為ｅｎａｃ阻抑劑之螺環胍化合物
AR070527A1 (es) * 2008-02-26 2010-04-14 Johnson Michael R Bloqueadores poliaromaticos del canal de sodio
CA3039943C (en) 2008-02-28 2021-07-13 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
SI2615085T1 (sl) 2008-03-31 2015-11-30 Vertex Pharmaceuticals Incorporated Piridilni derivati kot cftr-modulatorji
PL2358680T3 (pl) 2008-10-23 2013-08-30 Vertex Pharma Stałe postacie N-(4-(7-azabicyklo[2.2.1]heptan-7-ylo)-2-(trifluorometylo)fenylo)-4-okso-5-(trifluorometylo)-1,4-dihydrochinolino-3-karboksyamidu
US20100316628A1 (en) 2008-12-09 2010-12-16 The General Hospital Corporation Agents and methods for treating respiratory disorders
JP5699090B2 (ja) 2008-12-30 2015-04-08 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
AR086745A1 (es) * 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
KR20140047189A (ko) * 2012-10-04 2014-04-22 이영시 칼슘 함량이 높은 홍시 재배용 친환경 비료 및 이를 이용한 홍시의 제배방법

Also Published As

Publication number Publication date
ZA201504560B (en) 2019-10-30
JP6392243B2 (ja) 2018-09-19
IL239410A (en) 2017-09-28
WO2014099705A1 (en) 2014-06-26
CA2896686A1 (en) 2014-06-26
NZ709199A (en) 2020-06-26
HK1255811A1 (zh) 2019-08-30
IL239410A0 (en) 2015-07-30
AU2013363247B2 (en) 2018-03-22
IL253964B (en) 2019-11-28
CA2895555C (en) 2021-10-19
HK1215704A1 (zh) 2016-09-09
RU2015129076A (ru) 2017-01-25
CN108863956A (zh) 2018-11-23
JP2018197263A (ja) 2018-12-13
BR112015014062A2 (pt) 2017-07-11
EP2931711B1 (en) 2017-08-02
EP3323812A1 (en) 2018-05-23
CN104955812A (zh) 2015-09-30
CA2895555A1 (en) 2014-06-26
JP2016503031A (ja) 2016-02-01
AU2013363247A1 (en) 2015-07-02
EP3323812B1 (en) 2019-08-14
KR102258465B1 (ko) 2021-05-31
IL253964A0 (en) 2017-10-31
CN104955812B (zh) 2018-06-22
ES2644718T3 (es) 2017-11-30
MX2015007798A (es) 2015-08-20
AU2018204471A1 (en) 2018-07-12
ES2754617T3 (es) 2020-04-20
KR20150095869A (ko) 2015-08-21
EP2931711A1 (en) 2015-10-21
ES2674665T3 (es) 2018-07-03

Similar Documents

Publication Publication Date Title
IL253951A0 (en) Compounds 5,3-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide
IL242278A0 (en) Compounds 4)-n-fluoro-2-methoxy-5-nitrophenyl)pyrimidine-2-converted amine and their salts
ZA201501049B (en) 5,5-heteroaromatic anti-infective compounds
IL240196A0 (en) Amide compounds, preparations containing them and their uses
IL240195A0 (en) Pyridone amide compounds, preparations containing them and their uses
IL227815B (en) Pyrrolopyrazine-spirocyclic piperidine amide compounds, and preparations containing them and their uses
SG11201506829XA (en) Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
HK1215376A1 (zh) 取代的 -氟- -亞氨基- -甲基- -氧代- -二氫嘧啶- -甲醯胺衍生物
HUE041685T2 (hu) 2,3,3,3-Tetrafluor-propént tartalmazó készítmény
EP2881386A4 (en) amide
EP2699091A4 (en) 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS
HK1215703A1 (zh) -二氨基- -氯- -苯基丁基 甲脒基 吡嗪- -甲酰胺化合物
ZA201306229B (en) Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines
BR302013001134S1 (pt) Configuração aplicada em aspirador de pó.
HK1207080A1 (zh) -乙基- -羥基- -甲基- 甲基 -五羥基己基 氨基 -氧代- -苯基- -二氫喹啉- -甲酰胺
ZA201402903B (en) Amide compounds, compositions and applications thereof
HK1207317A1 (zh) 取代的 -萘啶
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
IL231468A0 (en) 3,1-diaryl-converted heterocyclic pesticides
HK1221456A1 (zh) -二取代環丁基化合物
ZA201508354B (en) Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
GB201220558D0 (en) Novel compounds 1
GB201211592D0 (en) 50/50 snack packet
GB201209192D0 (en) The T-Gap nail holder
GB201200242D0 (en) Hand tool aid .3

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221213